Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial

IMPORTANCE: Dual blockade of programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) may overcome immune checkpoint inhibition. It is unknown whether dual blockade can potentiate antitumor activity without compromising safety in patients with recurrent or metastati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Siu, Lillian L., Even, Caroline, Mesía, Ricard, Remenar, Eva, Daste, Amaury, Delord, Jean-Pierre, Krauss, Jürgen, Saba, Nabil F., Nabell, Lisle, Ready, Neal E., Braña, Irene, Kotecki, Nuria, Zandberg, Dan P., Gilbert, Jill, Mehanna, Hisham, Bonomi, Marcelo, Jarkowski, Anthony, Melillo, Giovanni, Armstrong, Jon M., Wildsmith, Sophie, Fayette, Jérôme
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439564/
https://ncbi.nlm.nih.gov/pubmed/30383184
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.4628
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados